Daily Anesthesiology Research Analysis
Today's top anesthesiology/critical care papers span sedation, ventilation physiology, and pain mechanisms. A meta-analysis shows ciprofol offers safer endoscopy sedation than propofol with less hypoxemia and hypotension. An international cohort links stronger inspiratory effort to higher lung stress/strain and worse gas exchange, while a mechanistic study uncovers an amygdala–nucleus accumbens pathway driving pain unpleasantness.
Summary
Today's top anesthesiology/critical care papers span sedation, ventilation physiology, and pain mechanisms. A meta-analysis shows ciprofol offers safer endoscopy sedation than propofol with less hypoxemia and hypotension. An international cohort links stronger inspiratory effort to higher lung stress/strain and worse gas exchange, while a mechanistic study uncovers an amygdala–nucleus accumbens pathway driving pain unpleasantness.
Research Themes
- Safer endoscopy sedation with ciprofol vs propofol
- Inspiratory effort, ventilation mode, and P-SILI risk
- Amygdala–accumbens circuitry for affective-motivational pain
Selected Articles
1. A nociceptive amygdala-striatal pathway modulating affective-motivational pain.
In rodent models, a nociceptive ensemble in the basolateral amygdala projects to a hotspot in the nucleus accumbens shell and drives affective-motivational pain behaviors. Optogenetic/chemogenetic inhibition of this BLA→accumbens pathway reduced both acute and chronic pain-related affective responses, while single-nucleus RNA-seq revealed injury-induced axonal/presynaptic remodeling.
Impact: This work identifies and causally validates a specific amygdala–accumbens circuit for pain unpleasantness, opening a path to mechanism-based analgesia targeting affective pain dimensions.
Clinical Implications: Although preclinical, the findings nominate the BLA→accumbens pathway as a candidate target for neuromodulation or circuit-specific pharmacology to reduce pain unpleasantness, potentially informing perioperative and chronic pain management strategies that go beyond nociception.
Key Findings
- Optogenetic inhibition of a nociceptive BLA ensemble reduced affective-motivational pain behaviors in chronic neuropathic pain.
- Single-nucleus RNA-seq revealed injury-induced changes in axonal and presynaptic organization genes in nociceptive BLA neurons.
- A nociceptive hotspot in the nucleus accumbens shell receives input from BLA nociceptive neurons; chemogenetic inhibition of this pathway attenuated pain-related behaviors.
- Axonal calcium imaging demonstrated pain-related transmission from amygdala to medial nucleus accumbens.
Methodological Strengths
- Multimodal approach: optogenetics, chemogenetics, single-nucleus RNA-seq, and axonal calcium imaging across acute and chronic pain models.
- Causal circuit interrogation linking specific projections to behavioral phenotypes.
Limitations
- Preclinical rodent models limit immediate translatability to human pain.
- Behavioral endpoints emphasize affective-motivational aspects; sensory-discriminative pain modulation was not the primary focus.
Future Directions: Translate findings to humans via imaging/neuromodulation studies targeting BLA–accumbens circuitry; develop circuit-selective modulators to attenuate pain affect without impairing protective nociception.
The basolateral amygdala (BLA) assigns valence to sensory stimuli, with a dedicated nociceptive ensemble encoding the negative valence of pain. However, the effects of chronic pain on the transcriptomic signatures and projection architecture of this BLA nociceptive ensemble are not well understood. Here, we show that optogenetic inhibition of the nociceptive BLA ensemble reduces affective-motivational behaviors in chronic neuropathic pain. Single-nucleus RNA sequencing revealed peripheral injury-induced changes in genetic pathways involved in axonal and presynaptic organization in nociceptive BLA neurons. Next, we identified a previously uncharacterized nociceptive hotspot in the nucleus accumbens shell that is innervated by BLA nociceptive neurons. Axonal calcium imaging of BLA projections to the accumbens and chemogenetic inhibition of this pathway revealed pain-related transmission from the amygdala to the medial nucleus accumbens, facilitating both acute and chronic pain affective-motivational behaviors. Together, this work defines a critical nociceptive amygdala-striatal circuit underlying pain unpleasantness across pain states.
2. Ciprofol vs propofol for gastrointestinal endoscopy sedation: a systematic review and meta-analysis.
Across nine studies (n=1860), ciprofol reduced hypotension, respiratory depression, hypoxemia, choking cough, and injection pain versus propofol, with only a modest, clinically trivial delay in awakening. Trial sequential analysis supported the conclusiveness of key safety outcomes, and a 0.4 mg/kg dose may further reduce involuntary movements.
Impact: Provides synthesis with trial sequential analysis indicating clinically meaningful safety advantages for ciprofol in endoscopy sedation, informing anesthetic selection.
Clinical Implications: Consider ciprofol as an alternative to propofol for GI endoscopy sedation, particularly in patients at risk for hypoxemia or hypotension; anticipate minimal impact on recovery time.
Key Findings
- Ciprofol significantly reduced hypotension (RR 0.75), respiratory depression (RR 0.71), and hypoxemia (RR 0.65) compared with propofol.
- Injection pain was markedly lower with ciprofol (RR 0.11), with comparable rates of bradycardia, dizziness, nausea, and vomiting.
- Awakening time was slightly longer by ~0.8 minutes, deemed not clinically significant; TSA confirmed conclusiveness for key safety outcomes.
Methodological Strengths
- Systematic review with trial sequential analysis to assess conclusiveness and control random errors.
- Consistent safety benefits across multiple adverse outcomes with assessment of publication bias.
Limitations
- Predominantly studies from a single country; generalizability beyond settings in China may be limited.
- Procedure duration and patient-risk heterogeneity may influence dizziness or other outcomes; granular subgroup data are limited.
Future Directions: Conduct multinational, pragmatic RCTs comparing ciprofol vs propofol in diverse endoscopy settings and higher-risk populations, including longer procedures; evaluate cost-effectiveness and environmental footprint.
BACKGROUND: Ciprofol, a propofol derivative, is increasingly used for sedation in China. However, the specific benefits of ciprofol in gastrointestinal endoscopic sedation have not been fully evaluated. This meta-analysis aimed to compare the efficacy and safety of ciprofol with propofol in gastrointestinal endoscopy. METHODS: Four public databases were searched for the relevant literature to February 1, 2025. Studies were excluded based on predefined criteria, and the characteristics and outcome data of each included study were collected. Subsequently, meta-analysis and trial sequential analysis (TSA) were performed using Review Manager 5.3 and TSA 0.9.5.10 Beta, respectively. RESULTS: Nine studies involving 1860 participants were included in this study. Compared with propofol, ciprofol significantly reduced rates of hypotension (risk ratio [RR] 0.75, 95% confidence interval [CI] 0.63-0.89), respiratory depression (RR 0.71, 95% CI 0.56-0.91), hypoxemia (RR 0.65, 95% CI 0.48-0.87), choking cough (RR 0.74, 95% CI 0.57-0.95), and injection pain (RR 0.11, 95% CI 0.06-0.22). Awakening time of ciprofol was slightly prolonged (mean difference 0.81 minutes, 95% CI 0.02-1.61), though not clinically significant. Bradycardia, involuntary movement, dizziness, nausea, and vomiting were comparable between the two groups ( P > 0.05). Moreover, TSA demonstrated that the results of hypotension, hypoxemia, respiratory depression, and injection pain observed in the current sample size were decisive. Regression analysis did not reveal any potential publication bias. CONCLUSIONS: Ciprofol offers notable advantages over propofol in gastrointestinal endoscopic sedation, including a lower incidence of injection pain, hypotension, respiratory depression, and hypoxemia. A dosage of 0.4 mg/kg of ciprofol may be an effective alternative to propofol, as it further reduces the risk of involuntary movements. However, caution is warranted, as ciprofol may increase the risk of dizziness during procedures lasting 10 minutes or longer.
3. Physiological Consequences of Breathing Effort According to the Mode of Ventilation During Acute Hypoxemic Respiratory Failure.
In a 15-center cohort (60 patients; 339,796 breaths), higher inspiratory effort (Pmus) was linked to increased surrogates of lung stress/strain and lower inspiratory alveolar pressure relative to PEEP, with effects varying by ventilation mode. These physiological signatures predicted subsequent worsening in oxygenation and lung compliance.
Impact: Provides real-world physiological evidence linking patient effort to P-SILI surrogates and deterioration in gas exchange, informing how ventilatory modes and sedation strategies should be tailored.
Clinical Implications: Monitor inspiratory effort (e.g., via esophageal pressure) and adjust ventilation modes to limit Pmus-driven stress/strain in AHRF; consider deeper sedation or controlled ventilation when excessive effort risks P-SILI.
Key Findings
- Across 339,796 breaths, greater Pmus was associated with higher driving trans-alveolar pressure (stress), larger tidal volumes (strain), and lower inspiratory alveolar pressure relative to PEEP.
- The relationships between effort and stress/strain varied by ventilation mode and patient-mechanical interactions (elastance, synchrony).
- Elevated effort-related stress/strain predicted subsequent worsening in oxygenation and decreases in lung compliance.
Methodological Strengths
- International multicenter dataset with esophageal pressure monitoring and breath-by-breath analysis.
- Mixed-effects modeling including interactions for mode, elastance, and synchrony.
Limitations
- Observational design limits causal inference; unmeasured confounders may persist.
- Sample size (60 patients) may limit generalizability across AHRF phenotypes.
Future Directions: Prospective interventional trials testing effort-limiting strategies (mode selection, sedation, partial neuromuscular blockade) guided by Pmus thresholds; validation of effort targets for preventing P-SILI.
RATIONALE: Excessive stress (distending pressure), strain (volume deformation), and drop in inspiratory alveolar pressure are proposed mechanisms for patient self-inflicted lung injury. OBJECTIVES: To dissect the influence of inspiratory effort, respiratory mechanics, and ventilation mode on lung stress, strain, and drop in inspiratory alveolar pressure; and explore their impact on oxygenation and lung compliance. METHODS: International cohort study analyzing respiratory recordings (esophageal pressure) of patients with acute hypoxemic respiratory failure. Association between muscular pressure (Pmus), surrogates of stress (driving trans-alveolar pressure), strain (tidal volume), and inspiratory alveolar pressure relative to PEEP were explored with mixed-models, including interactions for ventilation mode, respiratory system elastance, and synchrony. Association between these and changes in oxygenation and lung compliance were explored. MEASUREMENTS AND MAIN RESULTS: 60 patients from 15 centers represented 528 recordings (339,796 breaths). For each cmH CONCLUSION: Strong efforts are associated with high surrogates for lung stress, strain, and lower inspiratory alveolar pressure relative to PEEP, differently according to the mode of ventilation, being associated with subsequent worsening oxygenation and lung compliance.